Abstract
A post-hoc analysis of the phase 2 data was performed for the SARS-COV-2 subunit protein vaccine MVC-COV1901. Anti-spike IgG, neutralization assays with live virus and pseudovirus were used to demonstrate age-dependent vaccine-induced antibody response to the vaccine. Results showed that an association exists between age and immune responses to the vaccine, providing further support for the need of booster shots, especially for the older age groups.
Competing Interest Statement
CEL, YJL, ICT and CC are employees of Medigen Vaccine Biologics (Taipei, Taiwan) and they received grants from Taiwan Centres for Disease Control, Ministry of Health and Welfare, during the conduct of the study. YLL declares no competing interests.
Clinical Trial
NCT04695652
Funding Statement
The study was funded by Medigen Vaccine Biologics (study sponsor), the Taiwan Centers for Disease Control and Ministry of Health and Welfare.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial protocol and informed consent form were reviewed and approved by the ethics committees at the participating sites. The main institutional review board was Chang Gung Medical Foundation (Taoyuan, Taiwan), and other institutional review boards were the following institutes in Taiwan: National Taiwan University Hospital (Taipei), Taipei Veterans General Hospital (Taipei), Tri-Service General Hospital (Taipei), Taipei Medical University Hospital (Taipei), Taipei Municipal Wanfang Hospital (Taipei), Taoyuan General Hospital Ministry of Health and Welfare (Taoyuan), China Medical University Hospital (Taichung), Changhua Christian Hospital (Changhua County), National Cheng Kung University Hospital (Tainan), and Kaoshiung Medical University Hospital (Kaoshiung). The trial was done in accordance with the principles of the Declaration of Helsinki and good clinical practice guidelines.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
